Oral therapies that kill aging cells were found to boost the levels of alpha-Klotho, a protective protein that declines with age and safeguards animals against age-related diseases — including idiopathic pulmonary fibrosis (IPF) — in a study involving older mice. So-called senolytic therapies are designed to kill aging senescent…
News
Using nanoparticles to deliver an anti-scarring RNA molecule to pro-scarring lung macrophages — a type of immune cell — prevented and reduced lung tissue fibrosis in a mouse model of pulmonary fibrosis (PF), a study shows. To specifically target pro-fibrotic macrophages, researchers at University of Illinois College of Medicine (UICM)…
Abnormally high levels of the signaling molecule interleukin 19 (IL-19) were detected in lung tissues from both mice and humans with idiopathic pulmonary fibrosis (IPF) in a recent study. These findings indicate that IL-19 promotes IPF progression by activating the transforming growth factor-beta pathway, a key mediator of tissue…
Angion Biomedica plans to ask the U.S. Food and Drug Administration (FDA) for permission to start testing its experimental therapy ANG-3070 in people with idiopathic pulmonary fibrosis (IPF), the company announced. ANG-3070 is an oral medication designed to block the activity of multiple protein receptors that contribute to…
Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…
Healthcare providers involved in diagnosing and treating rare diseases believe that increased physician education and collaboration with specialized facilities will have the greatest positive impact on treating these conditions over the next five years, according to results from a 2021 survey. Definitive Healthcare, a healthcare commercial intelligence company, conducted…
An extract of the plant Lemna minor L., also called duckweed, suppresses the signs and symptoms of idiopathic pulmonary fibrosis (IPF) in disease-induced mice, a study suggests. More research to evaluate dosing and oral availability is recommended, study authors noted. “Pulmonary Protein Oxidation and Oxidative Stress…
Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy volunteers, with no reports of serious adverse events (side effects) or discontinuations, according to a Phase 1a trial. “We are pleased that LTI-03 has passed this important safety milestone as…
Coenzyme Q10 (CoQ10), an antioxidant found naturally in the body and some foods, may help airway basal stem cells survive and ease symptoms of idiopathic pulmonary fibrosis (IPF), a study in mice given both in a transplant suggests. Researchers observed that more airway basal stem cells, a type of…
The Translational Genomics Research Institute (TGen) will use a big-memory technology, called MemVerge Memory Machine Big Memory virtualization software, to accelerate research on the cellular mechanisms underlying idiopathic pulmonary fibrosis (IPF). “MemVerge Memory Machine has quickly resulted in research value for TGen,” Jonathan Jiang, chief operating officer of…
